Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in Care

Release Date: September 29, 2017
Expiration Date: September 29, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in Care features a summary of clinical evidence guiding best practices for the treatment of patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera, and myelofibrosis. This activity focuses on the important molecular and clinical features for diagnosis of these disorders, the nuances of risk stratification, current treatment approaches, as well as new potentially practice-changing approaches that may further advance the field, which are currently being evaluated in clinical trials. Interactive clinical vignettes are followed by short video interviews with leading experts in the management of patients with MPNs. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

CME/CE Activity Table of Contents

  • Module 1: Essential thrombocythemia
  • Module 2: Polycythemia vera
  • Module 3: Post-polycythemia vera myelofibrosis

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of hematological disorders. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with hematological disorders are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Explain mechanistic approaches to manage myeloproliferative neoplasms and their biologic rationale
  2. Discuss phenotypic drivers of myeloproliferative neoplasms and the implications for practice of new markers and diagnostic criteria
  3. Evaluate emerging clinical data regarding new agents and evolving strategies for myeloproliferative neoplasms
  4. Apply an evidence-based approach to optimize outcomes in the treatment of myeloproliferative neoplasms

Faculty, Staff, and Planners' Disclosures

Faculty

Ruben A. Mesa, MD, FACP
Chair, Division of Hematology & Medical Oncology
Deputy Director, Mayo Clinic Cancer Center
Professor of Medicine
Mayo Clinic
Phoenix, AZ

Disclosure: Grant Research Support: Incyte, Gilead, CTI BioPharma, NS Pharma, Promedior Consultant: Novartis, AOP

Daniel J. DeAngelo, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Institute Physician, Adult Leukemia Program
Dana-Farber Cancer Institute
Boston, MA

Disclosure: Consultant: Novartis, Amgen, Incyte Corporation, Pfizer, Takeda Pharmaceutical Company, Shire

John Mascarenhas, MD
Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosure: Grant Research Support: Incyte Corporation, Janssen Pharmaceutical, CTI BioPharma, Merck & Co., Roche Holding AG, Promedior Consultant: Novartis (DSMB), Incyte Corporation (Clinical Steering Contributing Trials)

Michael J. Mauro, MD
Leader, Myeloproliferative Neoplasms Program
Clinical Director, Leukemia Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, NY

Disclosure: No relevant financial relationships with commercial interests.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise






Become a Member

Forgot Password?
Filter By